Watabe Mika, Shima Atsushi, Takeda Kiyoaki, Terada Yuta, Sakato Yusuke, Nishida Akira, Wada Ikko, Sakamaki-Tsukita Haruhi, Yoshimura Kenji, Kambe Daisuke, Furukawa Koji, Sawamura Masanori, Nakanishi Etsuro, Taruno Yosuke, Yamakado Hodaka, Takahashi Ryosuke, Sawamoto Nobukatsu
Department of Human Health Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Clin Park Relat Disord. 2025 May 6;12:100341. doi: 10.1016/j.prdoa.2025.100341. eCollection 2025.
Pharmacological control of the motor symptoms of Parkinson's disease (PD) is challenging with disease progression. Device-aided therapies help relieve these symptoms but are invasive and require specific management. Induced pluripotent stem (iPS) cells avoid ethical concerns and may prevent immune rejection in autologous transplants. Allogeneic iPS cells are considerably more practical, despite potential concerns regarding tumor formation post-transplantation. The present study aimed to clarify the perceptions and acceptance of patients with PD regarding regenerative medicine, invasive surgical treatments (deep brain stimulation, levodopa-carbidopa intestinal gel), and cell transplantation (iPS cells, embryonic stem cells, fetal-derived cells).
This prospective cross-sectional survey of 102 patients with PD applied a new questionnaire based on a previous survey of the general public's perception of regenerative medicine.
Cell-based therapies were the most popular choice, with 86.1 % of responders choosing it, mainly due to "improvement in quality of life" (69.1 %), "the possibility of slowing the disease progression" (66.2 %), and "treatment effectiveness" (51.5 %). Among these patients, 47.1 % expected regenerative medicine to become the standard therapy within several years and 82.4 % believed that regenerative medicine was safe. Autologous iPS cells were accepted by 83.8 % of the patients, while 52.5 % accepted allogeneic iPS cells.
Patients had high expectations for the therapeutic effects of cell-based therapies and were optimistic about its early implementation and safety in regenerative medicine, with iPS cells being the most accepted for transplantation. The present findings should be confirmed in a larger cohort, as these findings are based on a limited sample.
随着帕金森病（PD）病情进展，对其运动症状进行药物控制具有挑战性。器械辅助疗法有助于缓解这些症状，但具有侵入性且需要特殊管理。诱导多能干细胞（iPS细胞）避免了伦理问题，并且可能防止自体移植中的免疫排斥。尽管存在移植后肿瘤形成的潜在担忧，但异体iPS细胞更为实用。本研究旨在阐明PD患者对再生医学、侵入性手术治疗（深部脑刺激、左旋多巴-卡比多巴肠凝胶）和细胞移植（iPS细胞、胚胎干细胞、胎儿来源细胞）的看法和接受程度。
这项对102例PD患者的前瞻性横断面调查采用了一份基于先前对公众对再生医学看法的调查的新问卷。
基于细胞的疗法是最受欢迎的选择，86.1%的受访者选择了它，主要原因是“生活质量改善”（69.1%）、“疾病进展可能放缓”（66.2%）和“治疗效果”（51.5%）。在这些患者中，47.1%期望再生医学在几年内成为标准疗法，82.4%认为再生医学是安全的。83.8%的患者接受自体iPS细胞，而52.5%的患者接受异体iPS细胞。
患者对基于细胞的疗法的治疗效果寄予厚望，并对其在再生医学中的早期应用和安全性持乐观态度，其中iPS细胞最被接受用于移植。由于这些发现基于有限的样本，应在更大的队列中进行验证。
